Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial

KEYNOTE-224 investigators

Research output: Contribution to journalArticlepeer-review

1134 Scopus citations

Fingerprint

Dive into the research topics of 'Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial'. Together they form a unique fingerprint.

Medicine & Life Sciences